Cargando…

Prognostic Impact of Elevation of Cancer Antigen 15-3 (CA15-3) in Patients With Early Breast Cancer With Normal Serum CA15-3 Level

PURPOSE: Cancer antigen 15-3 (CA15-3) is a serum tumor marker for breast cancer (BC) extensively used in clinical practice. CA15-3 is non-invasive, easily available, and a cost-effective tumor marker for immediate diagnosis, monitoring and prediction of BC recurrence. We hypothesized that an elevati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ryu, Jai Min, Kang, Danbee, Cho, Juhee, Lee, Jeong Eon, Kim, Seok Won, Nam, Seok Jin, Lee, Se Kyung, Kim, Yeon Jin, Im, Young-Hyuck, Ahn, Jin Seok, Park, Yeon Hee, Kim, Ji-Yeon, Lee, Hyunjong, Kang, Mira, Yu, Jong Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139845/ https://www.ncbi.nlm.nih.gov/pubmed/37051649 http://dx.doi.org/10.4048/jbc.2023.26.e17

Ejemplares similares

Use of CA15-3 for screening breast cancer: An antibody-lectin sandwich assay for detecting glycosylation of CA15-3 in sera
por: Choi, Jae Woong, et al.
Publicado: (2018)

Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry
por: Kim, Ji-Yeon, et al.
Publicado: (2019)

Permanent Chemotherapy‐Induced Alopecia in Patients with Breast Cancer: A 3‐Year Prospective Cohort Study
por: Kang, Danbee, et al.
Publicado: (2018)

Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry
por: Kim, Ji-Yeon, et al.
Publicado: (2021)

Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes
por: Kim, Ji-Yeon, et al.
Publicado: (2017)

Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience
por: Kim, Ji-Yeon, et al.
Publicado: (2022)

Pretreatment endocrine symptoms and recurrence-free survival among young premenopausal patients with breast cancer: a prospective cohort study
por: Kang, Danbee, et al.
Publicado: (2023)

PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis
por: Seo, Youjeong, et al.
Publicado: (2018)

Value of CA 15:3 in the follow-up of breast cancer patients.
por: Pons-Anicet, D. M., et al.
Publicado: (1987)

Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy
por: Kim, Ji-Yeon, et al.
Publicado: (2022)

Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma
por: Terävä, Joonas, et al.
Publicado: (2019)

Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study
por: Kang, Danbee, et al.
Publicado: (2021)

A train the trainer program for healthcare professionals tasked with providing psychosocial support to breast cancer survivors
por: Park, Eunyoung, et al.
Publicado: (2018)

Correlation of cancer antigen 15-3 (CA15-3) serum level and bony metastases in breast cancer patients
por: Fakhari, Ashraf, et al.
Publicado: (2019)

Prognostic value of ERBB4 expression in patients with triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

Effect of Ca-P compound formed by hydrothermal treatment on biodegradation and biocompatibility of Mg-3Al-1Zn-1.5Ca alloy; in vitro and in vivo evaluation
por: Kim, Yu-Kyoung, et al.
Publicado: (2017)

Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA.
por: Gion, M., et al.
Publicado: (1994)

Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance
por: Hing, J.X., et al.
Publicado: (2020)

Prediction Model for Postoperative Quality of Life Among Breast Cancer Survivors Along the Survivorship Trajectory From Pretreatment to 5 Years: Machine Learning–Based Analysis
por: Kang, Danbee, et al.
Publicado: (2023)

Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer
por: Shin, Junghoon, et al.
Publicado: (2023)

The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans
por: Kim, Hakyoung, et al.
Publicado: (2019)

Impact of Serum Lipid on Breast Cancer Recurrence
por: Jung, Sung Mi, et al.
Publicado: (2020)

A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jung, Hae Hyun, et al.
Publicado: (2023)

Antifungal effects of synthetic human β-defensin 3-C15 peptide
por: Lim, Sang-Min, et al.
Publicado: (2016)

Trends of axillary surgery in breast cancer patients with axillary lymph node metastasis: a comprehensive single-center retrospective study
por: Kim, Yeon Jin, et al.
Publicado: (2023)

Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases
por: Nicolini, Andrea, et al.
Publicado: (2006)

Diagnostic Value of Neuron-Specific Enolase (NSE) and Cancer Antigen 15-3 (CA 15-3) in the Diagnosis of Pleural Effusions
por: Saba, Mohammad Ali, et al.
Publicado: (2017)

Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
por: Jung, Hae Hyun, et al.
Publicado: (2021)

Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer
por: Kim, Nalee, et al.
Publicado: (2023)

Serum CA 15-3 assay in the diagnosis and follow-up of breast cancer.
por: Kallioniemi, O. P., et al.
Publicado: (1988)

Serum CEA and CA 15-3 as prognostic factors in primary breast cancer
por: Ebeling, F G, et al.
Publicado: (2002)

Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3
por: De Cock, L., et al.
Publicado: (2021)

Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a Prospective Cohort
por: Jo, Hyunji, et al.
Publicado: (2022)

Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy?
por: Cho, Won Kyung, et al.
Publicado: (2018)

Growth Differentiation Factor 15 Predicts Chronic Liver Disease Severity
por: Lee, Eaum Seok, et al.
Publicado: (2017)

Validation of Korean Version of the COmprehensive Score for Financial Toxicity (COST) among Breast Cancer Survivors
por: Shim, Sungkeun, et al.
Publicado: (2022)

Development of a Nomogram to Predict N2 or N3 Stage in T1–2 Invasive Breast Cancer Patients with No Palpable Lymphadenopathy
por: Kim, Isaac, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pc9q1d7n069lkk8237gda238ti